Market news

Travere Therapeutics (TVTX) said Wednesday that it received a notice of allowance from the US Patent

SAN DIEGO, September 23, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled "Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders," directed to certain methods of using FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). Upon issuance, the patent is expected to provide U.S. patent coverage for certain

Travere Therapeutics (NasdaqGM:TVTX) announced a planned CEO and President transition effective December 1, 2026. Dr. Eric Dube will step down from his roles as CEO and President as part of the scheduled leadership change. Bradley L. Campbell has been appointed to succeed Dr. Dube, bringing experience from the rare disease biopharmaceutical sector. This CEO and President transition at Travere Therapeutics is an important development to set alongside the rest of the analysis. We have also...

Tipranks Press Release.

Travere Therapeutics has delivered a very large share price gain over the past few years, which naturally puts the focus on what investors are paying for its sales today. With the stock now reflecting years of optimism, the immediate question is how well the current valuation lines up with the revenue the business is actually generating. Over the last 3 years the share price has risen by roughly 7x, so anyone looking at Travere Therapeutics now is effectively asking how much of that move is...

SAN DIEGO, September 21, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Company’s Board of Directors has unanimously appointed Bradley L. Campbell, former president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of BioMarin Pharmaceutical Inc., to succeed Dr. Dube as president and chief executive officer a

William E. Rote, Chief Research Officer, on September 15, 2026, sold 209,048 shares in Travere Thera

SAN DIEGO, September 17, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET.

SAN DIEGO, September 11, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on September 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 16 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 56,220 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan ("2018 Plan") but were granted outside of the 2018 Plan and were grante

Biotech stock Travere Therapeutics is not profitable yet, but a turnaround may be around the corner as shares hover in a buy zone.

Travere Therapeutics is Friday's IBD Stock Of The Day. As the Filspari story gets "sweeter," shares are clearing an entry.

These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Travere Therapeutics (NASDAQ:TVTX) is pursuing growth through expanded use of FILSPARI in rare kidney diseases while advancing a late-stage treatment candidate for classical homocystinuria and building its renal pipeline through the recently in-licensed BTK inhibitor civorebrutinib, Chief Financial

SAN DIEGO, August 12, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on August 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 12 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 38,940 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan ("2018 Plan") but were granted outside of the 2018 Plan and were granted as i

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Tipranks Press Release.

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Ligand stock landed in a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike.

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

SAN DIEGO, August 05, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences:

Travere Therapeutics (TVTX) has an average rating of buy and mean price target of $57.29, according